Clinical trials: Chronic Obstr Lung Disease
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a…
- Trial name
- NCT01627327
- Testing
- fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
- Where
- 54 sites in United States, Canada and 4 more
- Volunteers
- 623 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Nebulized Hypertonic Saline for Inpatient Use in COPD
A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.
- Trial name
- NCT02266875
- Testing
- hypertonic saline, standard saline
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- OhioHealth
Chronic Obstructive Pulmonary Disease
The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of chronic morbidity and mortality throughout the world, being the fourth leading cause of death in the world.
- Trial name
- NCT02680639
- Testing
- BiPAP Synchrony ventilator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Philips Respironics
Smoking Cessation
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
- Trial name
- NCT00285012
- Testing
- Varenicline Tartarate
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 504 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
Some patients with Chronic Obstructive Pulmonary Disease (COPD) report that they are uncertain whether they achieve clinical benefit using a dry-powder inhaler (DPI).
- Trial name
- NCT01391559
- Testing
- arformoterol, salmeterol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pulmonary Disease, Chronic Obstructive
Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IV multi-center, randomized, open-label, cross-over, placebo study in subjects with Chronic Obstructive Pulmonary Disease (COPD) to compare inhaler-specific preference attributes of two inhalers - ELLIPTA dry…
- Trial name
- NCT02786927
- Testing
- Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
- Where
- 22 sites in United States
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Major Depression
Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity.
- Trial name
- NCT00151372
- Testing
- Treatment Adherence Intervention, Enhanced Care
- Where
- 3 sites in United States
- Volunteers
- 141 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease (COPD)
Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the LINQ™ for COPD study is to characterize Reveal LINQ™ derived data from patients with COPD by assessing the relationship between changes in LINQ™ derived data with COPD exacerbation events.
- Trial name
- NCT04169529
- Testing
- Reveal LINQ
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease (COPD)
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.
- Trial name
- QUANTIFY (NCT01574651)
- Testing
- QVA149, Tiotropium, Formoterol
- Where
- 144 sites in Germany
- Volunteers
- 934 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Neuromuscular Electrical Stimulation in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to elucidate whether combination of usual pulmonary rehabilitation and neuromuscular electrical stimulation of quadriceps may improve exercise capacity in patients affected by chronic obstructive…
- Trial name
- NCT00677690
- Testing
- neuromuscular electrical stimulation (NMES)
- Where
- Italy
- Volunteers
- 83 people
- Sponsor
- Fondazione Salvatore Maugeri
Chronic Obstructive Pulmonary Disease
A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Objective: Chronic obstructive pulmonary disease (COPD) is a disease with significant morbidity and incurs heavy utilization of healthcare resources.
- Trial name
- NCT01108835
- Testing
- Comprehensive care programme
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- Chinese University of Hong Kong
Moderate to Severe COPD
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- Columbus (NCT00690482)
- Testing
- AZD1981
- Where
- 21 sites in Bulgaria, Denmark and 3 more
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
This study is designed to assess the effect of QVA149 (110/50 ug q.d.) versus placebo on pulmonary function and average physical activity levels in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- MOVE (NCT01996319)
- Testing
- QVA149
- Where
- 30 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the safety and efficacy of a single dosage strength of GW685698/GW642444 in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00731822
- Testing
- GW685698/GW642444
- Where
- 9 sites in Norway, Sweden
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study was to assess the effect of CK-2127107 relative to placebo on cycle ergometer exercise tolerance, assessed as change from period baseline in constant work rate (CWR) endurance time, utilizing a…
- Trial name
- NCT02662582
- Testing
- Reldesemtiv
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Global Development, Inc.
COPD
Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD
This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on…
- Trial name
- NCT02685293
- Testing
- GFF MDI (PT003)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT00606684
- Testing
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg
- Where
- 99 sites in United States, Argentina and 12 more
- Volunteers
- 602 people
- Sponsor
- GlaxoSmithKline